Search
prostate small cell carcinoma
Pathology:
- androgen-insensitive carcinoma
Clinical manifestations:
- visceral metastases
- lytic bone metastases
- bulky lymph node tumor mass
- bulky prostate tumor mass
Laboratory:
- serum prostate-specific antigen (PSA) < 10 ng/mL
Management:
- platinum-based chemotherapy
- carboplatin plus docetaxel (75 mg/m2) every 3 weeks
- salvage therapy upon disease progression
- etoposide (120 mg/m2) plus cisplatin (25 mg/m2) daily for 3 days every 3 weeks
General
small cell carcinoma
References
- Aparicio AM et al.
Platinum-based chemotherapy for variant castrate-resistant
prostate cancer.
Clin Cancer Res 2013 May 6
PMID: 23649003
http://clincancerres.aacrjournals.org/content/early/2013/05/04/1078-0432.CCR-12-3791